Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Read-GeneWAR:RDG +1.18%79 Operating Margin % is -10.39% as of Jun. 2026. GuruFocus rates WAR:RDG with a GF Score™ of 79/100 and a GF Value™ of zł6.47 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 947 Biotechnology companies, Read-Gene ranks better than 80.25% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. Read-Gene's Operating Income for the
three
months ended in Jun. 2026 was zł-0.43 Mil. Read-Gene's Revenue for the
three
months ended in Jun. 2026 was zł4.17 Mil. Therefore, Read-Gene's Operating Margin % for the quarter that ended in Jun. 2026 was -10.39%.
The historical rank and industry rank for Read-Gene's Operating Margin % or its related term are showing as below:
WAR:RDG'
s Operating Margin % Range Over the Past 10 Years
Min: -12.53 Med: 2.11 Max: 15.47
Current: 9.9
WAR:RDG's Operating Margin % is ranked better than 80.25% of 947
companies
in the Biotechnology industry
Industry Median: -81.34
vs WAR:RDG: 9.90
Read-Gene's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
Read-Gene's Operating Income for the
three
months ended in Jun. 2026 was zł-0.43 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was zł1.65 Mil.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Read-Gene Operating Margin % Related Terms
Read-Gene Operating Margin % Historical Data
* Premium members only.
The historical data trend for Read-Gene's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:RDG vs VRTX, REGN, MRNA: Operating Margin % Comparison
For the Biotechnology subindustry, Read-Gene's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Read-Gene Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Read-Gene's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Read-Gene's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Read-Gene's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Read-Gene (WAR:RDG) has a Operating Margin % of -10.39% as of Jun. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Read-Gene and its competitors. According to the industry distribution chart, Read-Gene ranks #187 out of 947 companies in the Biotechnology industry, placing it in the top 19.7%.
Is Read-Gene's Operating Margin % too high?
Read-Gene's current Operating Margin % is -10.39%. Based on the distribution chart, Read-Gene ranks #187 out of 947 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Read-Gene has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Read-Gene's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Read-Gene ranks #187 out of 947 companies for Operating Margin %. This places Read-Gene in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Read-Gene and its competitors. Read-Gene's current Operating Margin % is -10.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Read-Gene stock overvalued right now?
Based on GuruFocus' analysis, Read-Gene (WAR:RDG) is currently considered Modestly Undervalued. The stock's GF Value™ is zł6.47, compared to a current price of zł5.16 — trading 20.2% below its estimated fair value. The current Operating Margin % is -10.39%. Read-Gene's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Read-Gene (WAR:RDG), the current Operating Margin % is -10.39% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Read-Gene (WAR:RDG) Overvalued in 2026?
Based on GuruFocus' analysis, Read-Gene stock appears to be undervalued.
The current stock price of zł5.16 is trading 20.2% below its estimated GF Value™ of zł6.47.
GuruFocus considers Read-Gene to be Modestly Undervalued.
Key valuation signals for WAR:RDG:
Operating Margin %: -10.39%
GF Value™: zł6.47 vs. price of zł5.16 (20.2% below fair value)
No single metric tells the full story. See the WAR:RDG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours.
79GF Score
Get the complete analysis for WAR:RDG
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:RDG has been successfully added to your 
